These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34897643)

  • 41. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
    Najib J
    Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson's Disease Patients with Motor Fluctuations.
    Reichmann H; Eggert K; Oehlwein C; Warnecke T; Lees AJ; Kemmer M; Soares-da-Silva P
    Eur Neurol; 2022; 85(5):389-397. PubMed ID: 35350024
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations.
    Takeda A; Takahashi R; Tsuboi Y; Nomoto M; Maeda T; Nishimura A; Yoshida K; Hattori N
    Mov Disord; 2021 Feb; 36(2):415-423. PubMed ID: 33073879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease.
    Ferreira JJ; Poewe W; Rascol O; Stocchi F; Antonini A; Moreira J; Guimarães B; Rocha JF; Soares-da-Silva P
    Mov Disord; 2022 Nov; 37(11):2272-2283. PubMed ID: 36054562
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
    Poewe WH; Deuschl G; Gordin A; Kultalahti ER; Leinonen M;
    Acta Neurol Scand; 2002 Apr; 105(4):245-55. PubMed ID: 11939936
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Relevance of COMT inhibitors in the treatment of motor fluctuations].
    Jost WH; Buhmann C; Classen J; Eggert K; Kohl Z; Outeiro T; Tönges L; Woitalla D; Reichmann H
    Nervenarzt; 2022 Oct; 93(10):1035-1045. PubMed ID: 35044481
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Opicapone and acute levodopa challenge test: the big issue.
    Cavallieri F; Fioravanti V; Valzania F
    Acta Neurol Belg; 2021 Oct; 121(5):1347-1349. PubMed ID: 33471304
    [No Abstract]   [Full Text] [Related]  

  • 50. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
    Deane KH; Spieker S; Clarke CE
    Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Remarkable clinical responses of non-fluctuating Parkinson's disease (PD) after alternating catechol O-methyltransferase inhibitors: case series switching from entacapone 200 ~ 300 mg/day to opicapone 25 mg/day.
    Nakamagoe K; Tsuji H; Ishii K; Tamaoka A
    Neurol Sci; 2021 Nov; 42(11):4813-4814. PubMed ID: 34346016
    [No Abstract]   [Full Text] [Related]  

  • 52. Entacapone in the management of Parkinson's disease.
    Henchcliffe C; Waters C
    Expert Opin Pharmacother; 2002 Jul; 3(7):957-63. PubMed ID: 12083995
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Opicapone: Once-Daily COMT Inhibitor for the Treatment of Wearing Off in Parkinson's Disease.
    Craft BM; Baker DE; Levien TL
    Sr Care Pharm; 2022 Feb; 37(2):55-61. PubMed ID: 35082010
    [No Abstract]   [Full Text] [Related]  

  • 54. Safety and efficacy of tolcapone in Parkinson's disease: systematic review.
    Artusi CA; Sarro L; Imbalzano G; Fabbri M; Lopiano L
    Eur J Clin Pharmacol; 2021 Jun; 77(6):817-829. PubMed ID: 33415500
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical advantages of COMT inhibition with entacapone - a review.
    Gordin A; Kaakkola S; Teräväinen H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1343-63. PubMed ID: 15340869
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Opicapone and Levodopa-Carbidopa Intestinal Gel Infusion: The Way Forward Towards Cost Savings for Healthcare Systems?
    Leta V; van Wamelen DJ; Sauerbier A; Jones S; Parry M; Rizos A; Chaudhuri KR
    J Parkinsons Dis; 2020; 10(4):1535-1539. PubMed ID: 32597817
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of moderate liver impairment on the pharmacokinetics of opicapone.
    Rocha JF; Santos A; Falcão A; Lopes N; Nunes T; Pinto R; Soares-da-Silva P
    Eur J Clin Pharmacol; 2014 Mar; 70(3):279-86. PubMed ID: 24271646
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term safety and efficacy of opicapone in Japanese Parkinson's patients with motor fluctuations.
    Takeda A; Takahashi R; Tsuboi Y; Nomoto M; Maeda T; Nishimura A; Yoshida K; Hattori N
    J Neural Transm (Vienna); 2021 Mar; 128(3):337-344. PubMed ID: 33630140
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
    Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
    Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.